MX2023005579A - Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de la neuropatia provocada por o acompa?ada de la enfermedad de fabry. - Google Patents

Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de la neuropatia provocada por o acompa?ada de la enfermedad de fabry.

Info

Publication number
MX2023005579A
MX2023005579A MX2023005579A MX2023005579A MX2023005579A MX 2023005579 A MX2023005579 A MX 2023005579A MX 2023005579 A MX2023005579 A MX 2023005579A MX 2023005579 A MX2023005579 A MX 2023005579A MX 2023005579 A MX2023005579 A MX 2023005579A
Authority
MX
Mexico
Prior art keywords
preventing
fusion protein
farbry
attributed
disease
Prior art date
Application number
MX2023005579A
Other languages
English (en)
Inventor
Won Ki Kim
Cho Rong Park
Jin Young Kim
Sang Yun Kim
Su Yeon Park
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2023005579A publication Critical patent/MX2023005579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de una proteína de fusión de una enzima terapéutica y una región Fc de inmunoglobulina en la prevención o mejora de la neuropatía.
MX2023005579A 2020-11-13 2021-11-15 Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de la neuropatia provocada por o acompa?ada de la enfermedad de fabry. MX2023005579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200152246 2020-11-13
PCT/KR2021/016629 WO2022103220A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도

Publications (1)

Publication Number Publication Date
MX2023005579A true MX2023005579A (es) 2023-05-29

Family

ID=81601490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005579A MX2023005579A (es) 2020-11-13 2021-11-15 Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de la neuropatia provocada por o acompa?ada de la enfermedad de fabry.

Country Status (11)

Country Link
US (1) US20230416714A1 (es)
EP (1) EP4245310A1 (es)
JP (1) JP2023549322A (es)
KR (1) KR20220065720A (es)
CN (1) CN116419759A (es)
AU (1) AU2021377712A1 (es)
CA (1) CA3196264A1 (es)
CO (1) CO2023006516A2 (es)
IL (1) IL302857A (es)
MX (1) MX2023005579A (es)
WO (1) WO2022103220A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3650539A4 (en) * 2017-07-07 2021-08-18 Hanmi Pharm. Co., Ltd. NEW THERAPEUTIC ENZYMATIC FUSION PROTEIN AND ASSOCIATED USE
US20210009984A1 (en) * 2017-12-22 2021-01-14 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof

Also Published As

Publication number Publication date
CA3196264A1 (en) 2022-05-19
CO2023006516A2 (es) 2023-06-09
JP2023549322A (ja) 2023-11-24
KR20220065720A (ko) 2022-05-20
AU2021377712A1 (en) 2023-06-01
CN116419759A (zh) 2023-07-11
US20230416714A1 (en) 2023-12-28
WO2022103220A1 (ko) 2022-05-19
EP4245310A1 (en) 2023-09-20
IL302857A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
PH12020551865A1 (en) Anti-msr1 antibodies and methods of use thereof
ATE314475T1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
UA86350C2 (en) Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
BR0207749A (pt) Bactérias do ácido láctico como agentes para tratar e prevenir alergias
MX2022004577A (es) Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.
BR112021013415A2 (pt) Proteínas de fusão multifuncionais e usos das mesmas
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
IL165858A (en) Pharmaceutical preparation for treating human malignancies with arginine deprivation and uses thereof
WO2021151043A3 (en) Methods and compositions for treating and preventing viral infection
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
MX2023005579A (es) Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de la neuropatia provocada por o acompa?ada de la enfermedad de fabry.
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
ATE316136T1 (de) Nierenpolycystose-gen
GB0102145D0 (en) Substances
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
MX2023002013A (es) Region fc humana modificada de origen no natural del igg de union especifica al receptor fc modificado de origen no natural.
MX2023004034A (es) Métodos de tratamiento de la dermatomiositis.
MX2022008953A (es) Factores de transcripcion de proteina de dedos de zinc para reprimir la expresion de tau.